Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack
Background: To investigate the impact of colchicine adjuvant therapy on disease control and serum levels of nucleotide-binding oligomerization domain-like receptor (NALP) 3, soluble intercellular adhesion molecule (sICAM)-1, matrix metalloproteinase (MMP)-9, and MMP13 in patients with coronary heart...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Medical Biochemists of Serbia, Belgrade
2025-01-01
|
| Series: | Journal of Medical Biochemistry |
| Subjects: | |
| Online Access: | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582501046B.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832096631603855360 |
|---|---|
| author | Bingxun Wang Yongqing Liu Wenya Han Bing Li Pang Jie Wenwen Yang Zengcai Ma Zesheng Xu |
| author_facet | Bingxun Wang Yongqing Liu Wenya Han Bing Li Pang Jie Wenwen Yang Zengcai Ma Zesheng Xu |
| author_sort | Bingxun Wang |
| collection | DOAJ |
| description | Background: To investigate the impact of colchicine adjuvant therapy on disease control and serum levels of nucleotide-binding oligomerization domain-like receptor (NALP) 3, soluble intercellular adhesion molecule (sICAM)-1, matrix metalloproteinase (MMP)-9, and MMP13 in patients with coronary heart disease (CHD) complicated by acute gout attacks. Methods: Ninety-two patients with CHD and acute gout attacks admitted to our hospital from October 2021 to January 2023 were randomly divided into an observation group and a control group, with 46 patients in each group. The control group received conventional treatment, while the observation group received colchicine adjuvant therapy on top of the control group's treatment for 7 days. Clinical efficacy in both groups was assessed. Before and after treatment, cardiac function indicators (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular posterior wall thickness (LVPWT)), vascular endothelial function indicators (sICAM-1, endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF)), inflammatory factors (NALP3, MMP-9, MMP-13) levels, changes in immune cell populations (CD3+ lymphocytes, CD3+CD4+ lymphocytes, CD3+CD8+ lymphocytes ratio, and CD3+CD4+/CD3+CD8+ ratio) were compared, and the incidence of adverse reactions was recorded. Three months after treatment, the occurrence of major adverse cardiovascular events was also recorded. Results: The total effective rate in the observation group was significantly higher than that in the control group (93.48% vs 79.07%) (P<0.05). After treatment, the levels of NALP3, MMP-9, and MMP-13 in both groups decreased, with the observation group being lower than the control group (P<0.05). After treatment, LVPWT and LVEDD levels in the observation group were lower than those in the control group, and LVEF was higher (P<0.05). After treatment, the levels of ET-1 and sICAM-1 in the observation group were lower than those in the control group, and VEGF levels were higher (P<0.05). After treatment, the proportions of CD3+ lymphocytes, CD3+CD4+ lymphocytes, and CD3+CD4+/CD3+CD8+ ratio were significantly higher in the observation group than in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The occurrence of major adverse cardiovascular events in the observation group was lower than that in the control group (2.17% vs 13.04%). Conclusions: Colchicine adjuvant therapy improves the efficacy of CHD patients with acute gout attacks, helps improve cardiac function and vascular endothelial function, reduces serum levels of NALP3, sICAM-1, MMP-9, and MMP-13, enhances patient immunity, and controls disease progression. |
| format | Article |
| id | doaj-art-f065907aaa53419987508502d54cb1f0 |
| institution | Kabale University |
| issn | 1452-8258 1452-8266 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Society of Medical Biochemists of Serbia, Belgrade |
| record_format | Article |
| series | Journal of Medical Biochemistry |
| spelling | doaj-art-f065907aaa53419987508502d54cb1f02025-02-05T13:11:23ZengSociety of Medical Biochemists of Serbia, BelgradeJournal of Medical Biochemistry1452-82581452-82662025-01-01441465410.5937/jomb0-513261452-82582501046BEffects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attackBingxun Wang0Yongqing Liu1Wenya Han2Bing Li3Pang Jie4Wenwen Yang5Zengcai Ma6Zesheng Xu7Cangzhou Central Hospital, Department of Cardiology, Cangzhou, ChinaCangzhou Central Hospital, Department of Cardiology, Cangzhou, ChinaHebei Medical University, Cangzhou Central Hospital, Shijiazhuang, ChinaCangzhou Central Hospital, Department of Cardiology, Cangzhou, ChinaCangzhou Central Hospital, Department of Rheumatology, Cangzhou, ChinaCangzhou Central Hospital, Department of Rheumatology, Cangzhou, ChinaCangzhou Central Hospital, Department of Cardiology, Cangzhou, ChinaCangzhou Central Hospital, Department of Cardiology, Cangzhou, ChinaBackground: To investigate the impact of colchicine adjuvant therapy on disease control and serum levels of nucleotide-binding oligomerization domain-like receptor (NALP) 3, soluble intercellular adhesion molecule (sICAM)-1, matrix metalloproteinase (MMP)-9, and MMP13 in patients with coronary heart disease (CHD) complicated by acute gout attacks. Methods: Ninety-two patients with CHD and acute gout attacks admitted to our hospital from October 2021 to January 2023 were randomly divided into an observation group and a control group, with 46 patients in each group. The control group received conventional treatment, while the observation group received colchicine adjuvant therapy on top of the control group's treatment for 7 days. Clinical efficacy in both groups was assessed. Before and after treatment, cardiac function indicators (left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular posterior wall thickness (LVPWT)), vascular endothelial function indicators (sICAM-1, endothelin-1 (ET-1), and vascular endothelial growth factor (VEGF)), inflammatory factors (NALP3, MMP-9, MMP-13) levels, changes in immune cell populations (CD3+ lymphocytes, CD3+CD4+ lymphocytes, CD3+CD8+ lymphocytes ratio, and CD3+CD4+/CD3+CD8+ ratio) were compared, and the incidence of adverse reactions was recorded. Three months after treatment, the occurrence of major adverse cardiovascular events was also recorded. Results: The total effective rate in the observation group was significantly higher than that in the control group (93.48% vs 79.07%) (P<0.05). After treatment, the levels of NALP3, MMP-9, and MMP-13 in both groups decreased, with the observation group being lower than the control group (P<0.05). After treatment, LVPWT and LVEDD levels in the observation group were lower than those in the control group, and LVEF was higher (P<0.05). After treatment, the levels of ET-1 and sICAM-1 in the observation group were lower than those in the control group, and VEGF levels were higher (P<0.05). After treatment, the proportions of CD3+ lymphocytes, CD3+CD4+ lymphocytes, and CD3+CD4+/CD3+CD8+ ratio were significantly higher in the observation group than in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The occurrence of major adverse cardiovascular events in the observation group was lower than that in the control group (2.17% vs 13.04%). Conclusions: Colchicine adjuvant therapy improves the efficacy of CHD patients with acute gout attacks, helps improve cardiac function and vascular endothelial function, reduces serum levels of NALP3, sICAM-1, MMP-9, and MMP-13, enhances patient immunity, and controls disease progression.https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582501046B.pdfcolchicinecoronary heart diseaseacute gout attacknucleotide binding oligomerization domain-like receptor protein 3soluble intercellular adhesion molecule1matrix metalloproteinase-9matrix metalloproteinase13cardiac function |
| spellingShingle | Bingxun Wang Yongqing Liu Wenya Han Bing Li Pang Jie Wenwen Yang Zengcai Ma Zesheng Xu Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack Journal of Medical Biochemistry colchicine coronary heart disease acute gout attack nucleotide binding oligomerization domain-like receptor protein 3 soluble intercellular adhesion molecule1 matrix metalloproteinase-9 matrix metalloproteinase13 cardiac function |
| title | Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack |
| title_full | Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack |
| title_fullStr | Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack |
| title_full_unstemmed | Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack |
| title_short | Effects of colchicine adjuvant therapy on disease control, serum NALP3, sICAM-1, MMP-9 and MMP-13 in patients with coronary heart disease and acute gout attack |
| title_sort | effects of colchicine adjuvant therapy on disease control serum nalp3 sicam 1 mmp 9 and mmp 13 in patients with coronary heart disease and acute gout attack |
| topic | colchicine coronary heart disease acute gout attack nucleotide binding oligomerization domain-like receptor protein 3 soluble intercellular adhesion molecule1 matrix metalloproteinase-9 matrix metalloproteinase13 cardiac function |
| url | https://scindeks-clanci.ceon.rs/data/pdf/1452-8258/2025/1452-82582501046B.pdf |
| work_keys_str_mv | AT bingxunwang effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT yongqingliu effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT wenyahan effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT bingli effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT pangjie effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT wenwenyang effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT zengcaima effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack AT zeshengxu effectsofcolchicineadjuvanttherapyondiseasecontrolserumnalp3sicam1mmp9andmmp13inpatientswithcoronaryheartdiseaseandacutegoutattack |